The authors pooled race data from 13 of the trials that define current treatment of hypertrophic cardiomyopathy, covering 1,780 Black or White participants. Black patients were 3.98% of those participants, as compared to 16.5% of the US adult population. Where the trial sites sat predicted 26.4% Black enrolment, and Black adults less often meeting numerical entry criteria explained only 2.0% of the gap.
Why it is interesting: The disease is at least as common in Black Americans, yet neither site location nor entry criteria explains the shortfall.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.